San Francisco, CA (UroToday.com) — The Janssen Pharmaceutical Companies of Johnson & Johnson announced multiple data presentations from its prostate cancer and solid tumor portfolios will be featured at the European Society for Medical Oncology (ESMO) Annual Congress 2019, taking place September 27 to October 1 in Barcelona, Spain. Among Janssen’s 12 accepted abstracts are an oral presentation reporting updated overall survival results from the ERLEADA® (apalutamide) Phase 3 SPARTAN study in patients with non-metastatic castration-resistant prostate cancer (nmCRPC); patient-reported outcomes from the ERLEADA® Phase 3 TITAN study in patients with metastatic castration-sensitive prostate cancer (mCSPC), demonstrating preservation of overall health-related quality of life; and a late-breaking interim analysis from the Phase 2 GALAHAD study evaluating niraparib in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD).
“Janssen is focused on addressing areas of unmet need in both prostate cancer and solid tumors, and this year’s ESMO Annual Congress provides an opportunity to share these important study results for both approved and investigational therapies,” said Mark Wildgust, Ph.D., Vice President, Global Medical Affairs, Oncology, Janssen Research & Development, LLC. “In particular, we look forward to presenting new data for ERLEADA® and niraparib, which reinforce our continued commitment to improve outcomes for patients diagnosed with prostate cancer across the disease spectrum.”
Company-sponsored abstracts to be presented at the meeting include:
| Abstract No. | Title | Date/Time |
| ERLEADA® (apalutamide) | ||
| Oral Presentation | ||
| Abstract #843O | Apalutamide and Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): Updated Results from the Phase 3 SPARTAN Study |
Friday, September 27 2:39 PM – 2:51 PM CET |
| Poster Presentations | ||
| Abstract #851PD | Patient-Reported Outcomes (PROs) From TITAN: A Phase 3, Randomized, Double-Blind Study of Apalutamide Versus Placebo Added to Androgen Deprivation Therapy in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) |
Monday, September 30
12:00 PM CET |
| Abstract #883P | Androgen Receptor Aberrations in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Treated with Apalutamide Plus Androgen Deprivation Therapy in TITAN |
Monday, September 30
12:00 PM CET |
| Abstract #900TiP | A Phase 2 randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy with LHRH agonist or antagonist versus anti-androgen therapy with apalutamide in patients with biochemical progression after radical prostatectomy |
Monday, September 30
12:00 PM CET |
| Niraparib | ||
| Poster Presentations | ||
| Abstract #LBA50 | Pre-specified interim analysis of GALAHAD: A Phase 2 study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects |
Sunday, September 29
8:30 AM CET |
| Abstract #897TiP | A Phase 3 randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641) |
Monday, September 30
12:00 PM CET |
| Abstract #1412P | Analytical performance of the Resolution-HRD plasma assay used to identify mCRPC patients with biallelic disruption of DNA repair genes for treatment with niraparib |
Monday, September 30
12:00 PM CET |
| ZYTIGA® (abiraterone acetate) | ||
| Poster Presentation | ||
| Abstract #95P | Evaluation of markers associated with efficacy of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer (mCSPC) from the LATITUDE study |
Monday, September 30
12:00 PM CET |
| BALVERSA™ (erdafitinib) | ||
| Poster Presentations | ||
| Abstract #925P | Analysis of response to prior therapies and therapies after treatment with erdafitinib in fibroblast growth factor receptor (FGFR)-positive patients with metastatic urothelial carcinoma |
Monday, September 30
12:00 PM CET |
| Abstract #926P | Erdafitinib versus available therapies in advanced urothelial cancer: A matching adjusted indirect comparison |
Monday, September 30
12:00 PM CET |
| Abstract #932P | Hyperphosphatemia due to Erdafitinib (a Pan-FGFR Inhibitor) and Antitumor Activity Among Patients with Advanced Urothelial Carcinoma |
Monday, September 30
12:00 PM CET |
| Solid Tumor Portfolio | ||
| Poster Presentation | ||
| Abstract #488P | Correlation of Progression Free Survival-2 and Overall Survival in Solid Tumors | Saturday, September 28
2:00 PM CET |
Source: Johnson, Janssen. 2019. “Janssen to Highlight Depth of Prostate Cancer and Solid Tumor Portfolios with Multiple Data Presentations at ESMO 2019”. Prnewswire.com. https://www.prnewswire.com/news-releases/janssen-to-highlight-depth-of-prostate-cancer-and-solid-tumor-portfolios-with-multiple-data-presentations-at-esmo-2019-300919622.html.Further Related Content:
Read: ASCO GU 2018: First Presentation – SPARTAN: A Study of Apalutamide (ARN-509) in Men with Non-Metastatic Castration-resistant Prostate Cancer
Watch: Clinical Implications of TITAN in mHSPC – Kim Chi and Michael Morris
Titan Clinical Trial Information: NCT02489318
Watch: Interview with Kim Chi, MD – First Results of TITAN